Jackson News Reporter

DelveInsight Business Research LLP

DelveInsight’s “Cerebral Amyloid Angiopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cerebral Amyloid Angiopathy, historical and forecasted epidemiology as well as the Cerebral Amyloid Angiopathy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 Cerebral Amyloid Angiopathy Overview

Cerebral Amyloid Angiopathy also called cerebrovascular amyloidosis, is a cerebrovascular disorder caused by the accumulation of cerebral amyloid-β (Aβ) in the tunica media and adventitia of leptomeningeal and cortical vessels of the brain. The resultant vascular fragility tends to manifest in normotensive elderly patients as lobar intracerebral hemorrhage. It is a common cerebral amyloid deposition disease, affecting ~90% of Alzheimer’s patients and increasing the risk of stroke, brain hemorrhage, or dementia. The exact etiology of CAA is not fully understood. It is characterized by congophilic material (amyloid-beta 40 peptides) being deposited into the leptomeninges and small to medium-sized cerebral blood vessels. This deposition weakens vessel walls, making them prone to bleeding. CAA can occur in certain familial syndromes or can occur sporadically.

Cerebral Amyloid Angiopathy Epidemiology Insights:

• According to Kort et al. (2019), based on a neuropathological examination, the prevalence of moderate-to-severe Cerebral Amyloid Angiopathy in Alzheimer’s disease (AD) is 48% and in the general population 23%. The prevalence based on MRI criteria was remarkably lower: 22% in AD and 7% in the general population. 

• According to Robinson et al. (2011), the most serious manifestation in older people is the rupture of cerebral vessels, leading to primary intracerebral hemorrhage (PICH). PICH accounts for ∼10% of all strokes in the United Kingdom.

• According to Steven et al. (2022), the prevalence is strongly age-dependent. The prevalence of CAA ranged from 2.3% for patients between the ages of 65 and 74, 8.0% for those aged 75 to 84, and 12.1% in patients over the age of 85.

• According to Holmes et al. (2017), in a community-based autopsy cohort, CAA was shown to be more common in demented versus non-demented individuals with an overall frequency of 84.9% (13); 57.8% had mild to moderate CAA, and 18.9% had moderate to severe Cerebral Amyloid Angiopathy.

Click here to learn more about Cerebral Amyloid Angiopathy Market Landscape

The Report Covers the Cerebral Amyloid Angiopathy Epidemiology Segmented by –

• Cerebral Amyloid Angiopathy prevalent cases 

• Cerebral Amyloid Angiopathy incident cases 

• Cerebral Amyloid Angiopathy treatment cases 

• Cerebral Amyloid Angiopathy diagnosed cases 

Cerebral Amyloid Angiopathy Market Outlook 

The Cerebral Amyloid Angiopathy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cerebral Amyloid Angiopathy market trends by analyzing the impact of current Cerebral Amyloid Angiopathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Cerebral Amyloid Angiopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cerebral Amyloid Angiopathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Cerebral Amyloid Angiopathy market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies in the Cerebral Amyloid Angiopathy Market Include:

• Sorento Therapeutics 

• Prothena Therapeutics 

• Takeda Pharmaceuticals 

• Spectrum Pharmaceuticals 

• Millineum Pharmaceuticals 

• Alnylm Pharmaceuticals 

And many more 

Cerebral Amyloid Angiopathy Therapies Covered in the Report Include:

• Taxifolin 

• Galantamine 

• Rivastigmine 

• Donepezil 

• Aducanumab 

• Memantine 

And many others

Learn more about the Key Companies and the Emerging Therapies in the Cerebral Amyloid Angiopathy Market

Table of Contents 

1. Key Insights 

2. Report Introduction 

3. Executive Summary of Cerebral Amyloid Angiopathy  

4. Disease Background and Overview

5. Epidemiology and patient population

6. Cerebral Amyloid Angiopathy Emerging Therapies

7. Cerebral Amyloid Angiopathy Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Click here to read more about the report’s offerings @ Cerebral Amyloid Angiopathy Market Outlook 

Trending Reports by DelveInsight

• Adalimumab Biosimilar Market

• Arbovirus Infection Market

• Artificial Pancreas Device System Market

• Dental Equipment Market

• Gluten Sensitivity Market

• Hypothyroidism Market

• Inflammatory Bowel Disease Market

• Mayus Kinase Jak Inhibitors Market

• Mild Dry Eye Market

• Mucopolysaccharidosis Market

• Oncolytic Virus Cancer Therapy Market

• Pyoderma Gangrenosum Market

• Transdermal Drug Delivery Devices Market

• Intrathecal Pumps Market

• Hedgehog Pathway Inhibitors Market

• Yellow Fever Market

• Laryngeal Cancer Market

• Female Infertility Market

• Gender Dysphoria Market

• Chronic Brain Damage Market

• Spain Healthcare Outlook Market

• Malignant Fibrous Histiocytoma Market

Related Reports 

Cerebral Amyloid Angiopathy Pipeline Insights

The “Cerebral Amyloid Angiopathy – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Cerebral Amyloid Angiopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.

 About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services